BELITE BIO INC

Belite Bio unveils Phase 3 DRAGON results, spotlighting tinlarebant as a game‑changing oral therapy for age‑related retinal disease at Euretina.

Discover how San Diego‑based Belite Bio is tackling macular degeneration, liver disease and diabetes with breakthrough therapeutics—track their volatile stock, market cap, and future growth prospects.

Belite Bio, a Nasdaq‑listed San Diego biopharma, targets age‑related metabolic diseases like macular degeneration, liver disease, and diabetes with cutting‑edge therapeutics, promising long‑term returns amid volatile stock swings.

Belite Bio, Inc. is a clinical-stage biopharmaceutical company pioneering novel therapeutics for age-related metabolic diseases such as macular degeneration, liver disease, and diabetes.